ArticleBMC infectious diseases2025
A preliminary study on the clinical value of simultaneous amplification and testing for tuberculosis (SAT-TB) for early therapeutic monitoring in multidrug-resistant/rifampicin-resistant tuberculosis.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMultidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) poses a major global health challenge due to its complex treatment regimen and the lack of rapid and effective monitoring tools. Conventional methods, such as the long-culture-period MGIT™960 and molecular assays like Xpert, which cannot distinguish between viable and nonviable bacteria, are unable to meet the clinical demand for dynamic monitoring.
methodsA total of 125 patients with MDR/RR-TB diagnosed at Hangzhou Red Cross Hospital between January 2022 and October 2024 were included in the study. Sputum samples were collected at baseline (T0), the end of the 1st month of treatment (T1), and the end of the 2nd month of treatment (T2). Samples were tested using sputum simultaneous amplification and testing for tuberculosis (SAT-TB), acid-fast staining (AFS), and MGIT™960 culture. With MGIT™960 culture serving as the gold standard, the diagnostic performance of SAT-TB and AFS was evaluated in terms of sensitivity, specificity, and consistency using Kappa values and receiver operating characteristic curve analysis.
resultsAt T0, the sensitivity of sputum SAT-TB and AFS was 81.6% and 55.2%, respectively. At T1, SAT-TB demonstrated a sensitivity of 87.1% and specificity of 100.0% compared to 54.8% sensitivity and 98.9% specificity of AFS. Kappa values were 0.910 (SAT-TB) and 0.626 (AFS), with significant statistical differences (P < 0.05). Positive predictive values (PPV) were 100% and 94.4%, while negative predictive values (NPV) were 95.9% and 86.9% for SAT-TB and AFS, respectively. The area under the curve (AUC) values were 0.935 for SAT-TB and 0.769 for AFS, with a significant statistical difference (P = 0.0006). At T2, SAT-TB and AFS sensitivities declined to 25.0% and 16.7%, respectively, with respective specificities of 100.0% and 98.2%. The corresponding Kappa values were 0.376 and 0.212, with significant statistical differences (P < 0.05). PPVs were 100% and 50%, and NPVs were 92.6% and 91.7%. The AUC values dropped to 0.625 for SAT-TB and 0.574 for AFS, with no statistically significant difference (P = 0.2305).
conclusionSputum SAT-TB demonstrated superior sensitivity and specificity than AFS. At T1, it showed high consistency with MGIT™960 culture, suggesting that sputum SAT-TB is a promising tool for early therapeutic efficacy evaluation in MDR/RR-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.